Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease.

Cardiovascular drugs and therapy - 1 Apr 2007

Tsikouris James P, Peeters Michael J

Abstract excerpt

Renin Angiotensin System (RAS) inhibitors comprise some of the most commonly used medications in coronary artery disease (CAD) and its related syndromes. Unfortunately, significant inter-patient variability seems likely in response to these agents; of which, the influence of genetic determinants is of interest. This review summarizes the available RAS inhibitor pharmacogenomic studies which have evaluated RAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Angiotensin II Type 1 Receptor Blockers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Angiotensin Receptor Antagonists

Share to Coronary Artery Disease

Share to Coronary Stenosis

Share to Endpoint Determination

Share to Renin-Angiotensin System

Source

Identifiers

PMID: 17486303
DOI: 10.1007/s10557-007-6026-2

Genes

CAD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of renin angiotensin system inhibitors in coronary artery disease.PMID 17486303Read ↗

Cardiovascular pharmacogenomics: current status and future directions.Semantic proximity Read ↗

Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.Semantic proximity Read ↗

Genotype-based clinical trials in cardiovascular disease.Semantic proximity Read ↗

Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseasesSemantic proximity Read ↗

Pharmacogenomic biomarkers in coronary artery disease: a narrative review.Semantic proximity Read ↗

Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular MedicineSemantic proximity Read ↗

Applied pharmacogenomics in cardiovascular medicine.Semantic proximity Read ↗

Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.Semantic proximity Read ↗

ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?Semantic proximity Read ↗

Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension.Semantic proximity Read ↗

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.Semantic proximity Read ↗

Pharmacogenomics of statin response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.